Description

Premium PT 141 Peptide – 10mg Research Grade UK

Product Overview

If you are looking to source PT 141 for laboratory research, Cocer Peptides supplies a high-purity, research-grade version of this synthetic melanocortin receptor agonist. PT 141 is a cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (α-MSH) that acts as an agonist at melanocortin receptors including MC3R and MC4R, which are expressed primarily in the central nervous system according to the NIH PubMed database. Unlike traditional erectogenic compounds that act on the vascular system, this PT 141 peptide is studied for its interaction with the central nervous system, specifically for its ability to modulate neural pathways involved in behavioural responses.

Researchers sourcing this compound typically require research-grade material with complete analytical documentation. Every batch from Cocer Peptides includes a Certificate of Analysis (COA) showing HPLC purity and mass spectrometry confirmation. The molecular formula is C₅₀H₆₈N₁₄O₁₀ with a molecular weight of approximately 1025.18 g/mol, as documented in the FDA Global Substance Registration System. Additional structural details are catalogued in the NIH PubChem database, including CAS number 189691-06-3.

Regulatory Notice: This product is supplied strictly for laboratory research use only and is not intended for human or veterinary use. PT 141 (bremelanotide) is a prescription-only medicine in the UK. The Medicines and Healthcare products Regulatory Agency (MHRA) has warned against purchasing unlicensed medicines online, and the UK Government advises consumers to verify supplier credentials before making any purchase.

Product Specifications

Mechanism of Action

Melanocortin Receptor Agonism

PT 141 peptide functions as a non-selective agonist at melanocortin receptors, with primary activity at MC3R and MC4R. These receptors are expressed primarily in the central nervous system and are involved in regulating behavioural responses, as documented by researchers publishing through Frontiers in Endocrinology. Research indexed in the NIH PMC database has demonstrated that it activates MC4 receptors within the hypothalamus in experimental models.

Central Nervous System Pathway

Unlike PDE5 inhibitors that act peripherally on vascular smooth muscle, this compound works through a central mechanism. A 2022 study using fMRI scanning found that it significantly enhanced cerebellar and supplementary motor area activation in response to erotic visual stimuli compared with placebo, and increased amygdala-insula functional connectivity, according to research published in ScienceDirect. The authors interpreted this as the compound reducing cognitive-emotional barriers to sexual engagement rather than simply amplifying a peripheral signal.

Pharmacokinetic Profile

Following subcutaneous administration, PT 141 produces peak plasma concentrations at 60 minutes, with a mean Cmax value of 77.1 ng/ml following the therapeutic dose of 1.75 mg. The half-life is approximately 2–3 hours, with pharmacodynamic effects lasting up to 16 hours, as noted in the FDA prescribing information. As a peptide, metabolism involves hydrolysis of amide bonds to release the drug’s constitutive amino acids, with free amino acids primarily cleared through the urine.

Research Applications

Neuroendocrine Signalling Research

PT 141 peptide is used as a molecular probe for studying melanocortin receptor signalling and GPCR-mediated intracellular signalling pathways. Researchers investigate receptor binding affinity, signalling bias, and comparative behaviour relative to other melanocortin analogues, with relevant structural data indexed in the NIH PubMed database. The compound is particularly valuable for examining the integration of psychological and physiological arousal mechanisms.

Sexual Dysfunction Research

This compound is one of the most studied peptides for sexual dysfunction. Early-phase RCTs in male populations found statistically significant erectogenic responses on RigiScan at doses greater than 7 mg, with onset of the first erection occurring in approximately 30 minutes, as reported in The BMJ. In premenopausal women with sexual arousal disorder, a 2006 study found that significantly more women reported moderate or high sexual desire after treatment versus placebo. These trials support the biological plausibility of PT 141 for sexual dysfunction research, though no Phase 3 trials in men have been conducted.

Blood Pressure Research

Research published in the Journal of Hypertension evaluated the use of ambulatory blood pressure monitoring to assess the compound’s cardiovascular effects. Reported side effects in clinical research have included transient changes in blood pressure, nausea, flushing, and headaches, with additional safety data catalogued in the NIH PMC database.

Quality and Purity

Every batch of Cocer Peptides PT 141 undergoes rigorous quality control:

• ≥99% purity verified by HPLC

• Molecular weight confirmed by mass spectrometry

• Batch number matching the vial label

• Certificate of Analysis (COA) available on request

Independent testing platforms such as Finnrick publish third-party lab results for this peptide from various suppliers, with purity standards typically requiring HPLC purity of at least 99.5%. For researchers sourcing PT 141 peptide, verifying COA documentation is essential for ensuring product integrity and experimental reproducibility. The UK Government also provides guidance on verifying the legitimacy of research chemical suppliers.

Frequently Asked Questions

What is PT 141?

PT 141 (bremelanotide) is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (α-MSH). It acts as an agonist at melanocortin receptors including MC3R and MC4R, which are expressed primarily in the central nervous system, as documented in the NIH PubChem database.

How does it differ from other erectile dysfunction treatments?

Unlike PDE5 inhibitors that act peripherally on vascular smooth muscle, PT 141 peptide works through a central nervous system mechanism. Research suggests it may reduce cognitive-emotional barriers to sexual engagement rather than simply amplifying a peripheral vascular signal, according to studies indexed in ScienceDirect.

What is the purity of Cocer Peptides PT 141?

Our PT 141 is provided at ≥99% purity, verified by HPLC with third-party testing.

How should it be stored?

Store lyophilized powder at -20°C, desiccated and protected from light. Reconstituted material should be stored at 2–8°C and used promptly following standard laboratory protocols, as recommended by the FDA prescribing information.

Is this product suitable for human use?

No. This product is supplied strictly for research purposes only and is not intended for human or veterinary use. It is a prescription-only medicine in the UK and should only be supplied following a clinical assessment by a qualified healthcare professional, as stated by the MHRA.

Conclusion

PT 141 peptide represents a well-characterised research tool for investigating melanocortin receptor pharmacology, central nervous system signalling, and neuroendocrine pathways. Its unique mechanism—working through MC3R and MC4R in the central nervous system rather than peripheral vascular pathways—distinguishes it from other compounds studied in sexual dysfunction research, with supporting data published through Frontiers in Endocrinology. For scientists seeking PT 141 for laboratory applications, Cocer Peptides offers high-purity material with complete analytical documentation and batch-specific COA support.

Ready to Advance Your Research?

Order premium PT 141 10mg for your laboratory today.

Buy PT 141 Now | Contact Our Research Team